🇺🇸 FDA

Company profile · Sponsor

Janssen-Cilag

Janssen-Cilag International N.V.

E6DB09A · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Janssen-Cilag (E6DB09A) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E6DB09A
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. -, Apalutamide placebo, JNJ-56021927

    Janssen-Cilag

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. -, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927

    Janssen-Cilag

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  3. ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg

    Janssen-Cilag

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  4. BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283

    Janssen-Cilag

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  5. CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB

    Janssen-Cilag

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  6. Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules

    Janssen-Cilag

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  7. EFGARTIGIMOD ALFA, JNJ-80202135

    Janssen-Cilag

    generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  8. Enbrel 50 mg solution for injection in pre-filled syringe, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab 0.5 mL Varioject Placebo, Enbrel 25 mg powder and solvent for solution for injection

    Janssen-Cilag

    Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  9. Erbitux 5 mg/mL solution for infusion, JNJ-61186372, Erbitux 5 mg/mL solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., BEVACIZUMAB

    Janssen-Cilag

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  10. Film-Coated Tablet without Deucravacitinib, Film-Coated Tablet without JNJ-77242113, DEUCRAVACITINIB, JNJ-77242113

    Janssen-Cilag

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  11. Film-Coated Tablet without JNJ-77242113, JNJ-77242113

    Janssen-Cilag

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  12. Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas

    Janssen-Cilag

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  13. Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg

    Janssen-Cilag

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  14. GEMCITABINE , JNJ-17000139, MITOMYCIN

    Janssen-Cilag

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  16. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  17. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  18. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  19. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  20. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  21. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  22. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  23. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  24. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Janssen-Cilag?

Janssen-Cilag (E6DB09A) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Janssen-Cilag sponsor?

We track 24 ClinicalTrials.gov-linked programs for Janssen-Cilag, including -, Apalutamide placebo, JNJ-56021927 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Janssen-Cilag company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.